Lyos

TEAM II - Bone, Cancers and Metastases

INSERM UMR 1033 - TEAM II

UFR de Médecine Lyon-Est - 2ème étage rue Guillaume Paradin, 69372 Lyon cedex08 – France | Phone : +33(0)4 78 77 10 77

LYOS – INSERM U1033,
Team «Bone, Cancers and Metastases»,

Université de Lyon, France.

Top 10 publications over the past 5 years

 

  1. BOUCHET M, LAINÉ A, BOYAULT C, PROPONNET-GUERAULT M, MEUGNIER E, BOUAZZA L, KAN CWS, GERACI S, EL-MOGHRABI S, HERNANDEZ-VARGAS H, BENETOLLO C, YOSHIKO Y, DUTERQUE-COQUILLAUD M, CLÉZARDIN P, MARIE JC, BONNELYE E. ERRα expression in bone metastases leads to an exacerbated anti-tumor immune response. Cancer Res. 2020 May 4. pii: canres.3584.2019. doi: 10.1158/0008-5472.CAN-19-3584. [Epub ahead of print]
  2. PUPPO M, TAIPALENMÄKI H, HESSE E, CLÉZARDIN P. Non-coding RNAs in bone remodelling and bone metastasis: Mechanisms of action and translational relevance. Br J Pharmacol. 2019 Aug 18. doi: 10.1111/bph.14836. [Epub ahead of print]
  3. VARGAS G, BOUCHET M, BOUAZZA L, REBOUL P, BOYAULT C, GERVAIS M, KAN C, BENETOLLO C, BREVET M, CROSET M, MAZEL M, CAYREFOURCQ L, GERACI S, VACHER S, PANTANO F, FILIPITS M, DRIOUCH K, BIECHE I, GNANT M, JACOT W, AUBIN JE, DUTERQUE-COQUILLAUD M, ALIX-PANABIÈRES C, CLÉZARDIN P, BONNELYE E. ERRα promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors. Oncogene. 2019 Feb;38(7):950-964. doi: 10.1038/s41388-018-0579-3.
  4. CROSET M, PANTANO F, KAN CWS, BONNELYE E, DESCOTES F, ALIX-PANABIÈRES C, LECELLIER CH, BACHELIER R, ALLIOLI N, HONG SS, BARTKOWIAK K, PANTEL K, CLÉZARDIN P. MicroRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis-associated genes.Cancer Res. 2018 Sep 15;78(18):5259-5273. doi: 10.1158/0008-5472.CAN-17-3058.
  5. LELIÈVRE L, CLÉZARDIN P, MAGAUD L, ROCHE L, TUBIANA-MATHIEU N, TIGAUD JD, TOPART D, RABAN N, MOURET-REYNIER MA, MATHEVET P. Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancer With Serum VEGF as Primary Endpoint: The NEOZOL Study. Clin Breast Cancer. 2018 Dec;18(6):e1311-e1321. doi: 10.1016/j.clbc.2018.07.005.
  6. SOUSA S, CLÉZARDIN P. Bone-Targeted Therapies in Cancer-Induced Bone Disease. Calcif Tissue Int. 2018; 102(2):227-250. doi: 10.1007/s00223-017-0353-5.
  7. BOUDOT C, HÉNAUT L, THIEM U, GERACI S, GALANTE M, SALDANHA P, SAIDAK Z, SIX I, CLÉZARDIN P, KAMEL S, MENTAVERRI R. Overexpression of a functional calcium-sensing receptor dramatically increases osteolytic potential of MDA-MB-231 cells in a mouse model of bone metastasis through epiregulin-mediated osteoprotegerin downregulation. Oncotarget. 2017; 8(34):56460-72. doi: 10.18632/oncotarget.16999.
  8. REYNAUD C, FERRERAS L, DI MAURO P, KAN C, CROSET M, BONNELYE E, PEZ F, THOMAS C, AIMONT G, KARNOUB AE, BREVET M, CLEZARDIN P. Lysyl oxidase is a strong determinant of tumor cell colonization in bone. Cancer Res. 2017; 77(2):268-278. doi: 10.1158/0008-5472.CAN-15-2621.
  9. FRADET A, BOUCHET M, DELLIAUX C, GERVAIS M, KAN C, BENETOLLO C, PANTANO F, VARGAS G, BOUAZZA L, CROSET M, BALA Y, LEROY X, ROSOL TJ, RIEUSSET J, BELLAHCÈNE A, CASTRONOVO V, AUBIN JE, CLÉZARDIN P, DUTERQUE-COQUILLAUD M, BONNELYE E. Estrogen related receptor alpha in castration-resistant prostate cancer cells promotes tumor progression in bone. Oncotarget 2016, 7(47):77071-86. doi: 10.18632/oncotarget.12787.
  10. HADJI P, COLEMAN RE, WILSON C, POWLES TJ, CLÉZARDIN P, AAPRO M, COSTA L, BODY JJ, MARKOPOULOS C, SANTINI D, DIEL I, DI LEO A, CAMERON D, DODWELL D, SMITH I, GNANT M, GRAY R, HARBECK N, THURLIMANN B, UNTCH M, CORTES J, MARTIN M, ALBERT US, CONTE PF, EJLERTSEN B, BERGH J, KAUFMANN M, HOLEN I. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Ann Oncol. 2016; 27(3):379-90. doi: 10.1093/annonc/mdv617.